Peptide
Rezafungin (Rezzayo)
Rezafungin is a second-generation cyclic lipopeptide echinocandin antifungal. FDA-approved March 2023 for candidemia and invasive candidiasis - first new echinocandin in over a decade. ReSTORE Phase 3 trial (n=199): Noninferior to caspofungin for day-14 global cure and 30-day mortality. Weekly dosing (vs daily for other echinocandins) enables outpatient treatment. Inhibits (1,3)-beta-D-glucan synthase to disrupt fungal cell wall.
- Updated
- How we grade
- 31 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 1
- Outcomes
- 6
- Graded outcomes
- 3210
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Efficacy by Candida SpeciesImproves (the measure goes up)
- Day-14 Global CureImproves (the measure goes up)
- 30-Day All-Cause Mortality
Safety notes in the studies
- May avoid need for central venous catheter.
Studies cited
31 studies from PubMed
- Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin.
- Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany.
- Rezafungin: A Review in Invasive Candidiasis.
- Early use of the novel antifungal rezafungin: a case series and literature review.
- Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study.
- Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis
- Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults
- Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials
- Formulary Drug Review: Rezafungin
- Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study
- New antifungals development: rezafungin in candidiasis treatment.
- A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin.
- Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
- Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy).
- Pneumocystis jirovecii pneumonia in people living with HIV: a review.
- Formulary Drug Review: Rezafungin.
- Game Changer or More of the Same? A Comparative Meta-analysis of Rezafungin and Caspofungin in Treating Candidemia and Invasive Candidiasis.
- Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
- An exciting time for antifungal therapy
- Rezafungin and invasive candida infections: a new game changing antifungal?
- Echinocandins - structure, mechanism of action and use in antifungal therapy.
- Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
- A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects.
- Rezafungin: a novel antifungal for the treatment of invasive candidiasis.
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
- Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
- Erratum to: Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
- Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
- Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data.
- Rezafungin: First-in-Class Echinocandin for Invasive Candidiasis and Invasive Aspergillosis Prophylaxis
- Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy.